Clinical trials: Chronic Obstructive Pulmonary Disease, completed
Infection, Heart Failure
Rural Home Hospital: Proof of Concept
This study examines the implications of providing hospital-level care in rural homes.
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT04531280
- Testing
- Home hospital care
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Disease, Chronic Obstructive
HHHFA in COPD Patients, With Chronic Bronchitis
Heated, humidified high-flow air (HHHFA) devices improve airway clearance. HHHFA use for an average of 1.6 hours a day in COPD patients with chronic bronchitis improves health-related quality of life, lung function, and delays…
- Trial name
- NCT03959982
- Testing
- HHHFA Device, Spirometry, 6-minute walk
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Spyridon Fortis
Tracheitis, Tracheobronchitis
Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR
This post-marketing observational study (PMOS) will be conducted in a prospective, single-arm, single-country, multicenter format.
- Conditions
- Tracheitis, Tracheobronchitis, Bronchitis, Chronic Bronchitis
- Trial name
- NCT01130883
- Where
- 135 sites in Czechia
- Volunteers
- 3,130 people
- Sponsor
- Abbott
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the…
- Trial name
- NCT01085045
- Testing
- PT003 MDI, PT005 MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 118 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD, COPD Exacerbation
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders
- Trial name
- NCT01443845
- Testing
- Roflumilast
- Where
- 338 sites in United States, Argentina and 15 more
- Volunteers
- 2,354 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD), Emphysema
Home Pulmonary Rehabilitation for COPD
Regular physical activity has been found to be important in maintaining health and well-being in people with COPD. The purpose of this study is to test new technology and health coaching aimed to help people with COPD become more…
- Trial name
- NCT03480386
- Testing
- Home Based Pulmonary Rehabilitation
- Where
- 3 sites in United States
- Volunteers
- 375 people
- Sponsor
- Mayo Clinic
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days
The study drug which is an inhaled bronchodilator (lung airway relaxant)has been given to both healthy volunteers and to COPD patients before. This study will assess a new formulation of GSK573719.
- Trial name
- NCT00732472
- Testing
- GSK573719
- Where
- 7 sites in United Kingdom
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Effectiveness of Interventions to Teach Respiratory Inhaler Technique (E-TRaIN)
The purpose of this study is to evaluate the relative effectiveness of two different ways to teach subjects while hospitalized how to use respiratory inhalers and to follow-up after discharge home from the hospital to determine…
- Trial name
- E-TRaIN (NCT01426581)
- Testing
- Teach-To-Goal, Brief Intervention
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Chicago
Pulmonary Disease, Chronic Obstructive
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered…
- Trial name
- NCT00400153
- Testing
- Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg)
- Where
- 180 sites in United States, Argentina and 11 more
- Volunteers
- 1,480 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01662986
- Testing
- tiotropium bromide
- Where
- 50 sites in United States
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via…
- Trial name
- TRILOGY (NCT01917331)
- Testing
- Beclometasone/Formoterol/Glycopyrrolate, Beclometasone/Formoterol
- Where
- Hungary
- Volunteers
- 1,368 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD
The purpose of this study is to investigate the effect on exercise tolerance, lung function and symptoms after treatment with Symbicort, Oxis or placebo in patients with severe chronic obstructive pulmonary disease.
- Trial name
- CODEX (NCT00489853)
- Testing
- budesonide/formoterol Turbuhaler 320/9µg, formoterol Turbuhaler 9µg
- Where
- 9 sites in Germany, Switzerland
- Volunteers
- 137 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Comparative Effectiveness of COPD Treatments
To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the combination of a long-acting bronchodilators (LABA and the long-acting muscarinic antagonists (LAMA) tiotropium…
- Trial name
- NCT03376295
- Testing
- LABA and the LAMA tiotropium (LABA-TIO), LABA and an ICS (LABA-ICS)
- Where
- Canada
- Volunteers
- 3,954 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and efficacy of the fixed combination product QVA149 versus the component products QAB149 and NVA237, administered concurrently, in patients that have moderate to severe chronic obstructive pulmonary…
- Trial name
- BEACON (NCT01529632)
- Testing
- QVA149, NVA237, QAB149
- Where
- 26 sites in Austria, Denmark and 3 more
- Volunteers
- 193 people
- Sponsor
- Novartis Pharmaceuticals
Respiratory Disorders
Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific
Since the infectious aetiology of AECOPD has been suggested to vary according to geographical region, the primary purpose of this study (which will be conducted in several countries in Asia Pacific) is to evaluate the occurrence…
- Trial name
- NCT03151395
- Testing
- Sputum and blood sampling
- Where
- 19 sites in Hong Kong, Philippines and 2 more
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive (COPD)
Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to compare in COPD patients naïve to DPIs, the perception of the Breezhaler® and Ellipta® devices' feedback mechanisms evaluated using a preference questionnaire.
- Trial name
- Advantage (NCT02551224)
- Testing
- Patient preference questionnaire
- Where
- 10 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Lung Disease
Effect of Symbicort ® on GR in Sputum in COPD
The purpose of the research (or "knowledge gap" this research is designed to fill) is to understand the science of how the combination therapy of 2 drugs (inhaled longacting beta-agonists(LABA) and inhaled corticosteroids (ICS)…
- Trial name
- NCT01787097
- Testing
- Symbicort® total dose 400ug/12ug, Symbicort® total dose 800ug/24ug, Formoterol 24ug
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Imperial College London
Pulmonary Disease, Chronic Obstructive
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 micrograms tiotropium bromide solution for inhalation, delivered by the Respimat inhaler, once daily for four weeks in…
- Trial name
- NCT00696020
- Testing
- BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, Respimat® Inhaler
- Where
- 37 sites in United States, Canada and 1 more
- Volunteers
- 360 people
- Sponsor
- Boehringer Ingelheim
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA